CTOs on the Move

Sierra By The Sea

www.sierrabythesea.com

 
Sierra by the Sea is a beachfront residential drug addiction rehab & mental health treatment facility. Offering evidence-based addiction treatment for adults.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

PuraMed

PuraMed is a Schofield, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Northern New England Compounding Pharmacy

Northern New England Compounding Pharmacy is a Littleton, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elite Body Sculpture

At Elite Body Sculpture our biggest focus is making sure that every client that walks out the door is not just satisfied, but elated with their new, trimmer, sexier body. How do we do that? Mainly, we focus on liposuction and ONLY liposuction. At ...

Myonexustx

Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first-ever, corrective treatments for Limb-girdle muscular dystrophy.

PACT Pharma

PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.